Challenges for gene therapy of CNS disorders and implications for Parkinson's disease therapies

Affiliations

Comment

Martin Broadstock et al. Hum Gene Ther. 2012 Apr.

. 2012 Apr;23(4):340-3.

doi: 10.1089/hum.2012.2507. Epub 2012 Apr 10.

¹ Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College London, London SE1 1UL, United Kingdom. martin.1.broadstock@kcl.ac.uk

No abstract available

Comment on

Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates.
Samaranch L, Salegio EA, San Sebastian W, Kells AP, Foust KD, Bringas JR, Lamarre C, Forsayeth J, Kaspar BK, Bankiewicz KS. Samaranch L, et al. Hum Gene Ther. 2012 Apr;23(4):382-9. doi: 10.1089/hum.2011.200. Epub 2012 Mar 28. Hum Gene Ther. 2012. PMID: 22201473 Free PMC article.
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.
Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P, Kaplan PL, Forsayeth J, Aminoff MJ, Bankiewicz KS. Mittermeyer G, et al. Hum Gene Ther. 2012 Apr;23(4):377-81. doi: 10.1089/hum.2011.220. Epub 2012 Apr 10. Hum Gene Ther. 2012. PMID: 22424171 Free PMC article. Clinical Trial.